- Report
- August 2022
- 120 Pages
Global
From €4397EUR$4,500USD£3,671GBP
- Report
- November 2021
- 102 Pages
Global
From €4397EUR$4,500USD£3,671GBP
- Report
- March 2023
- 350 Pages
Europe
From €2637EUR$2,699USD£2,201GBP
- Report
- January 2022
- 115 Pages
Global
From €4641EUR$4,750USD£3,874GBP
- Report
- January 2022
- 70 Pages
Global
From €684EUR$700USD£571GBP
€977EUR$1,000USD£816GBP
- Report
- January 2022
- 125 Pages
Global
From €1368EUR$1,400USD£1,142GBP
€1954EUR$2,000USD£1,631GBP
- Report
- January 2022
- 70 Pages
Global
From €684EUR$700USD£571GBP
€977EUR$1,000USD£816GBP
- Report
- January 2022
- 90 Pages
Global
From €1368EUR$1,400USD£1,142GBP
€1954EUR$2,000USD£1,631GBP
- Report
- January 2022
- 150 Pages
Global
From €1026EUR$1,050USD£856GBP
€1466EUR$1,500USD£1,224GBP
- Report
- January 2022
- 70 Pages
Global
From €1368EUR$1,400USD£1,142GBP
€1954EUR$2,000USD£1,631GBP
- Report
- January 2022
- 125 Pages
Global
From €1710EUR$1,750USD£1,427GBP
€2443EUR$2,500USD£2,039GBP
- Report
- January 2022
- 90 Pages
Global
From €1368EUR$1,400USD£1,142GBP
€1954EUR$2,000USD£1,631GBP
- Report
- January 2022
- 125 Pages
Global
From €1710EUR$1,750USD£1,427GBP
€2443EUR$2,500USD£2,039GBP
- Report
- January 2022
- 90 Pages
Global
From €1368EUR$1,400USD£1,142GBP
€1954EUR$2,000USD£1,631GBP
- Report
- January 2022
- 60 Pages
Global
From €1026EUR$1,050USD£856GBP
€1466EUR$1,500USD£1,224GBP
- Report
- January 2022
- 60 Pages
Global
From €1026EUR$1,050USD£856GBP
€1466EUR$1,500USD£1,224GBP
- Report
- January 2022
- 60 Pages
Global
From €1026EUR$1,050USD£856GBP
€1466EUR$1,500USD£1,224GBP
- Report
- January 2022
- 60 Pages
Global
From €1368EUR$1,400USD£1,142GBP
€1954EUR$2,000USD£1,631GBP
- Report
- January 2022
- 60 Pages
Global
From €1026EUR$1,050USD£856GBP
€1466EUR$1,500USD£1,224GBP
- Report
- September 2024
- 82 Pages
Japan
From €3420EUR$3,500USD£2,855GBP
The Biosimilars and Biosuperiors market is a rapidly growing sector of the pharmaceutical industry. Biosimilars are biologic drugs that are highly similar to an existing biologic drug, while biosuperiors are biologic drugs that are more effective than an existing biologic drug. Biosimilars and biosuperiors are used to treat a variety of conditions, including cancer, autoimmune diseases, and inflammatory diseases.
Biosimilars and biosuperiors are developed using advanced biotechnology techniques, such as recombinant DNA technology and monoclonal antibody technology. These drugs are designed to be more cost-effective than their original counterparts, while still providing the same therapeutic benefits.
The Biosimilars and Biosuperiors market is expected to continue to grow in the coming years, as more biologic drugs are developed and approved for use. Companies in this market include Amgen, Pfizer, Merck, and Novartis. Show Less Read more